title: Oral vanoxerine prevents reinduction of atrial tachyarrhythmias: preliminary results.
abstract: BACKGROUND
  Vanoxerine is a promising, new, investigational antiarrhythmic drug. The purpose of this study was to test the hypothesis that oral dosing of vanoxerine would first terminate induced atrial flutter (AFL) and atrial fibrillation (AF), and then prevent their reinduction.
  
  
  METHODS
  In 5 dogs with sterile pericarditis, on the fourth day after creating the pericarditis, we performed electrophysiologic (EP) studies at baseline, measuring atrial excitability, refractoriness (AERP), and conduction time (CT) when pacing from the right atrial appendage, Bachmann's bundle (BB), and the posteroinferior left atrium at cycle lengths (CLs) of 400, 300, and 200 ms. Then, after induction of AFL or AF, all dogs received hourly oral doses of vanoxerine: 90 mg, followed by 180 mg and 270 mg. Blood was obtained to determine plasma vanoxerine concentrations at baseline, every 30 minutes, when neither AFL nor AF were inducible, and, finally, 1 hour after the 270 mg dose. Then we repeated the baseline EP studies.
  
  
  RESULTS
  Four dogs had inducible, sustained AFL, and 1 dog only had induced, nonsustained AF. In 4 AFL episodes, oral vanoxerine terminated the AFL and then rendered it noninducible after an average of 111 minutes (range 75-180 minutes) after the first dose was administered. The mean vanoxerine plasma level at the point of noninducibility was 84 ng/mL, with a narrow range of 76-99 ng/mL. In the dog with induced, nonsustained AF, it was no longer inducible at a drug level of 75 ng/mL. Vanoxerine did not significantly (1) prolong the AERP except at BB, and then only at the faster pacing CLs; (2) change atrial excitability thresholds; (3) prolong atrial conduction time, the PR interval, the QRS complex or the QT interval.
  
  
  CONCLUSIONS
  Orally administered vanoxerine effectively terminated AFL and rendered it noninducible. It also suppressed inducibility of nonsustained AF. These effects occurred at consistent plasma drug levels. Vanoxerine's insignificant or minimal effects on measured electrophysiologic parameters are consistent with little proarrhythmic risk.
authors: Division of Cardiovascular Medicine, Department of Medicine, Harrington McLaughlin Heart and Vascular Institute, University Hospitals Case Medical Center, Cleveland, Ohio 44106, USA. Ivan.Cakulev@case.edu
authors: Ivan
authors: I
authors: Cakulev
authors: Antonio E
authors: AE
authors: Lacerda
authors: Celeen M
authors: CM
authors: Khrestian
authors: Kyungmoo
authors: K
authors: Ryu
authors: Arthur M
authors: AM
authors: Brown
authors: Albert L
authors: AL
authors: Waldo
references: J Chromatogr. 1991 Nov 15;571(1-2):305-11
references: 1839795
references: J Pharm Sci. 1993 Nov;82(11):1164-6
references: 8289134
references: N Engl J Med. 2000 Mar 30;342(13):913-20
references: 10738049
references: J Cardiovasc Electrophysiol. 2010 Mar;21(3):311-9
references: 19817929
references: Curr Opin Investig Drugs. 2000 Oct;1(2):241-51
references: 11249581
references: J Am Coll Cardiol. 2003 Jan 15;41(2):255-62
references: 12535819
references: J Am Coll Cardiol. 1986 Oct;8(4):872-9
references: 3760359
references: J Cardiovasc Electrophysiol. 2008 Jan;19(1):74-81
references: 17900256
references: Am J Cardiol. 1980 Apr;45(4):732-41
references: 7361663
references: J Cardiovasc Electrophysiol. 1998 Aug;9(8 Suppl):S18-25
references: 9727671
references: J Am Coll Cardiol. 1996 Sep;28(3):707-12
references: 8772760
references: J Cardiovasc Electrophysiol. 2010 Mar;21(3):301-10
references: 19817928
references: J Cardiovasc Electrophysiol. 2004 Dec;15(12):1444-50
references: 15610294
references: Br J Clin Pharmacol. 1993 Mar;35(3):308-10
references: 8471409
references: JAMA. 2007 Sep 19;298(11):1312-22
references: 17878423
references: Circ Res. 1966 May;18(5):502-18
references: 5937541
references: J Am Coll Cardiol. 1991 Apr;17(5):1223-34
references: 2007723
references: J Am Coll Cardiol. 2003 Jul 2;42(1):20-9
references: 12849654
references: J Am Coll Cardiol. 1997 Feb;29(2):376-84
references: 9014992
references: Int Clin Psychopharmacol. 1990 Oct;5(4):237-51
references: 2150527